71289-64-0

Usage

Uses

Used in Pharmaceutical Industry:
3-[(2,4-DICHLOROBENZYL)OXY]BENZALDEHYDE is used as an intermediate in the synthesis of various pharmaceuticals and organic compounds. Its unique structure and properties make it a valuable component in the development of new drugs and therapies for various diseases.
Used in Medicinal Chemistry:
3-[(2,4-DICHLOROBENZYL)OXY]BENZALDEHYDE is used as a valuable compound in the field of medicinal chemistry. Its potential as an anti-tumor and anti-inflammatory agent has been studied, making it a promising candidate for the development of new drugs and therapies for various diseases.
Used in Drug Development:
3-[(2,4-DICHLOROBENZYL)OXY]BENZALDEHYDE has been studied for its potential use in the development of new drugs and therapies for various diseases. Its wide range of biological and pharmacological activities make it a valuable compound for researchers and scientists working in the field of drug development.

InChI:InChI=1/C14H10Cl2O2/c15-12-5-4-11(14(16)7-12)9-18-13-3-1-2-10(6-13)8-17/h1-8H,9H2

Upstream product

• 94-99-5 2,4-Dichlorobenzyl chloride 
• 100-83-4 meta-hydroxybenzaldehyde 

Downstream Products

• 467451-33-8 (Z)-5-(3-((2,4-dichlorobenzyl)oxy)benzylidene)-2-thioxoimidazolidin-4-one 
• 71289-83-3 1-[3-(2,4-Dichloro-benzyloxy)-phenyl]-butan-1-ol 

Relevant academic research and scientific papers

Computer-Aided Search for 5-Arylideneimidazolone Anticancer Agents Able To Overcome ABCB1-Based Multidrug Resistance

ABCB1 modulation is an interesting strategy in the search for new anticancer agents that can overcome multidrug resistance (MDR). Hence, 17 new 5-arylideneimidazolones containing an amine moiety, as potential ABCB1 inhibitors, were designed, synthesized, and investigated. The series was tested in both parental (PAR) and multidrug-resistant (MDR) ABCB1-overexpressing T-lymphoma cancer cells using cytotoxicity assays. The ABCB1-modulating activity was examined in rhodamine 123 accumulation tests, followed by Pgp-Glo Assay to determine the influence of the most active compounds on ATPase activity. Lipophilic properties were assessed both, in silico and experimentally (RP-TLC). Pharmacophore-based molecular modelling toward ABCB1 modulation was performed. The studies allowed the identification of anticancer agents (p-fluorobenzylidene derivatives) more potent than doxorubicin, with highly selective action on MDR T-lymphoma cells (selectivity index >40). Most of the investigated compounds showed ABCB1-modulating action; in particular, two 5-benzyloxybenzylidene derivatives displayed activity nearly as strong as that of tariquidar.

Synthesis and biological evaluation of tryptophan-derived rhodanine derivatives as PTP1B inhibitors and anti-bacterial agents

Several series of novel tryptophan-derived rhodanine derivatives were synthesized and identified as potential competitive PTP1B inhibitors and antibacterial agents. Among the compounds studied, 10b was found to have the best in vitro inhibition activity against PTP1B (IC50 = 0.36 ± 0.02 μM). In addition, the compounds also showed potent inhibition against other PTPs, especially CDC25B. Molecular docking analysis demonstrated that compounds 7c and 10b could occupy both the catalytic site and the adjacent pTyr binding site simultaneously. The compounds also showed higher levels of activity against gram-positive strains, the gram-negative strain Escherichia coli 1924, and multidrug-resistant gram-positive bacterial strains. Compounds 7c, 8c, 9e, 10a, and 10c had comparable or more potent antibacterial activity than the positive controls.

Synthesis and biological evaluation of dihydrotriazine derivatives as potential antibacterial agents

A series of 1,4-dihydro-1,3,5-triazine derivatives were designed and synthesized and their antibacterial and antifungal activities were evaluated. Most of the synthesized compounds showed potent inhibition of several Gram-positive bacterial strains (including multidrug-resistant clinical isolates) and Gram-negative bacterial strains, with minimum inhibitory concentrations (MICs) in the range of 2.1–181.2?μmol/L. Compounds 7a and 7c presented the most potent inhibitory activities against Gram-positive bacteria (e.g., Staphylococcus aureus 4220), Gram-negative bacteria (e.g., Escherichia coli 1924), and the fungus Candida albicans 7535, with MICs of 2.1 or 4.1?μmol/L. Especially, compound 7a was the most potent, with an MIC of 2.1?μmol/L against four multidrug-resistant, Gram-positive bacterial strains. The cytotoxic activity of the compound 7a, 7c and 7f was assessed in HepG2 cells, and the results suggest that 1,4-dihydro-1,3,5-triazine derivatives bearing a 6-benzyloxynaphthalen moiety are interesting scaffolds for the development of novel antibacterial agents.

Imidazo[2,1-b]thiazoles, imidazo[2,1-b]imidazoles and pyrrolo[1,2-c]imidazoles. Synthesis, structure and evaluation of benzodiazepine receptor binding

As a continuation of our studies on bicyclic heterocycles with benzodiazepine receptor affinity, derivatives with a 5:5 bicyclic skeleton, namely imidazo[2,1-b]thiazoles, imidazo[2,1-b]imidazoles and pyrrolo[1,2-c]imidazoles were prepared. The compounds p